Trial Profile
A protocol based treatment for debilitating fibrosing skin disorders with (anti-CD-20), rituximab
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Sep 2014
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Circumscribed scleroderma; Eosinophilic fasciitis
- Focus Adverse reactions; Therapeutic Use
- 23 Sep 2014 New trial record